产品封面图

雌激素受体α/β抗体

收藏
  • ¥1200
  • Biorigin
  • BN41502R
  • 2026年02月25日
  • IHC-P,ICC,
  • Human,Mouse,Rat,Pig,
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 适应物种

      Human,Mouse,Rat,Pig,

    • 应用范围

      IHC-P,ICC,

    • 抗体英文名

      Estrogen Receptor alpha + beta

    • 规格

      50ul

    英文名称 Estrogen Receptor alpha + beta
    中文名称 雌激素受体α/β抗体
    别    名 Estrogen Receptor alpha/beta; Atherosclerosis, susceptibility to, included; DKFZp686N23123; ER Alpha; ER; ER Beta; ER-alpha; ER-beta; ER[a]; ER[b]; Era; ERalpha; Erb; Erb2; ERbeta; ESR; ESR BETA; ESR1; ESR1_HUMAN; ESR2; ESRA; ESRB; Estr; Estra; Estradiol Receptor alpha; Estradiol receptor; Estradiol Receptor beta; ESTRB; Estrogen receptor 1 (alpha); Estrogen Receptor 1; Estrogen receptor 2 (ER beta); Estrogen Receptor 2; Estrogen receptor 2 ER beta; Estrogen receptor alpha; Estrogen receptor; Estrogen receptor beta 4; Estrogen resistance, included; HDL cholesterol, augmented response of, to hormone replacement, included; Myocardial infarction, susceptibility to, included; NR3A1; NR3A2; Nuclear receptor subfamily 3 group A member 1; Nuclear receptor subfamily 3 group A member 2; OTTHUMP00000017718; OTTHUMP00000017719; RNESTROR.  

     

     

     

     

    研究领域 肿瘤  染色质和核信号  信号转导  内分泌病  肿瘤细胞生物标志物  表观遗传学  
    抗体来源 Rabbit
    克隆类型 Polyclonal
    交叉反应 Human, Rat,  (predicted: Mouse, Pig, )
    产品应用 WB=1:500-2000 ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1ug/Test ICC=1:100 IF=1:100-500 (石蜡切片需做抗原修复)
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    分 子 量 66kDa
    细胞定位 细胞核 细胞浆 细胞膜 
    性    状 Liquid
    浓    度 1mg/ml
    免 疫 原 KLH conjugated synthetic peptide derived from human Estradiol Receptor alpha + beta:201-300/595 
    亚    型 IgG
    纯化方法 affinity purified by Protein A
    储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存条件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
    PubMed PubMed
    产品介绍 The estrogen receptor (ER) is a 66 kDa protein that mediates the actions of estrogens in estrogen responsive tissues. It is a member of a large superfamily of nuclear hormone receptors that function as ligand activated transcription factors. The ER gene consists of more than 140 kb of genomic DNA divided into 8 exons. These translate into a protein with six functionally discrete domains, labeled A through F. A second form of the estrogen receptor, ER beta has recently been described. The ER is an important regulator of growth and differentiation in the mammary gland. Presence of ER in breast tumors indicates an increased likelihood of response to anti estrogen (e.g. tamoxifen) therapy.

    Function:
    Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.

    Subunit:
    Binds DNA as a homodimer. Can form a heterodimer with ESR2. Isoform 3 can probably homodimerize or heterodimerize with isoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1C and NCOA3 coactivator (By similarity). Interacts with EP300; the interaction is estrogen-dependent and enhanced by CITED1. Interacts with CITED1; the interaction is estrogen-dependent. Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7; the interaction is a ligand-inducible. Interacts with PHB2, PELP1 and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interacts with KDM5A. Interacts with SMARD1. Interacts with HEXIM1. Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7 beta-estradiol (E2) and enhances ERS1-mediated transcription. Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform 4 of TXNRD1. Interacts with MLL2. Interacts with ATAD2 and this interaction is enhanced by estradiol. Interacts with KIF18A and LDB1. Interacts with RLIM (via C-terminus). Interacts with MACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4A blocks binding to PLCG and inhibits estrogen-induced cell proliferation. Interacts with DYNLL1. Interacts with CCDC62 in the presence of estradiol/E2; this interaction seems to enhance the transcription of target genes. Interacts with NR2C1; the interaction prevents homodimerization of ESR1 and suppresses its transcriptional activity and cell growth. Interacts with DYX1C1. Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC and PTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only in the presence of SAV1 and vice-versa. Binds to CSNK1D. Interacts with NCOA2; NCOA2 can interact with ESE1 AF-1 and AF-2 domains simultaneously and mediate their transcriptional synergy. Interacts with DDX5. Interacts with NCOA1; the interaction seems to require a self-association of N-terminal and C-terminal regions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3. Interacts with NRIP1 (By similarity).

    Subcellular Location:
    Isoform 1: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=A minor fraction is associated with the inner membrane.
    Isoform 3: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell membrane; Single-pass type I membrane protein. Note=Associated with the inner membrane via palmitoylation (Probable). At least a subset exists as a transmembrane protein with a N-terminal extracellular domain.
    Nucleus. Golgi apparatus. Cell membrane. Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated.

    Tissue Specificity:
    Widely expressed. Isoform 3 is not expressed in the pituitary gland.

    Post-translational modifications:
    Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably enhances transcriptional activity. Self-association induces phosphorylation.
    Glycosylated; contains N-acetylglucosamine, probably O-linked.
    Ubiquitinated. Deubiquitinated by OTUB1.
    Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization.
    Palmitoylated (isoform 3). Not biotinylated (isoform 3).
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor.

    Similarity:
    Belongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.

    SWISS:
    P03372

    Gene ID:
    2099

    Database links:

    Entrez Gene: 2099 Human

    Entrez Gene: 13982 Mouse

    Entrez Gene: 24890 Rat

    Omim: 133430 Human

    SwissProt: P49884 Cow

    SwissProt: P03372 Human



    Important Note:
    This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

    类固醇受体(Steroid Receptors)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    image.png

    image.png

    image.png

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 【求助】关于gsk3-beta功能的疑问

      a look from the following website just by clicking "Tyrosine Phosphorylation and Dimerization" http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WSN-43F85YV-2&_user=1111158&_coverDate=06%2F29%2F2001&_rdoc=1&_fmt=full&_orig=search

    • 【资源】中肽生化-多肽合成技术系列 Stapled Peptides

      -alkenylglycine用于每一种Stapled Peptide的生成,通常命名为XY,X表示在烯基侧链中a-carbon的空间化学位置(Cahn-Ingold-Prelog命名),Y表示长度。在固相多肽合成的过程中,α-甲基化,α-alkenylglycine交联氨基酸并入了合适的的位置。i, i+3StapledPeptide在i和i+3位置反别需要一单位的R5和S5. i,i+4 Stapled Peptide需要两单位的S5并入在对应的i和i+4位置。i,i+7 Stapled Peptide在i位置需要

    • CD11a/CD11b/CD11c分子

      CD11a/CD11b/CD11c 分子 CDlla 常用单克隆抗体或代号:MHM24, 2F12; CRIS―3(LFA―lα链,整合素α1) 主要表达细胞:Leu[A5] 分子质量(kDa)和结构:spl80(整合素α) 功 能:与1CAM-l(CD54)、ICAM-2(CDl02)、ICAM-3(C1350)结合,介导细胞黏附;与JAMl结合,参与白细胞穿过内皮细胞

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥580
    北京百奥莱博科技有限公司
    2025年07月15日询价
    ¥2400
    深圳市豪地华拓生物科技有限公司
    2025年07月14日询价
    询价
    上海莼试生物技术有限公司
    2026年02月27日询价
    ¥1250
    上海泽叶生物科技有限公司
    2025年07月08日询价
    询价
    上海一研生物科技有限公司
    2025年07月14日询价
    雌激素受体α/β抗体
    ¥1200